Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

Inclusion Criteria: * Undergoing orthotopic liver or split liver allograft transplantation * Female subject of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain effective birth control during the study Exclusion Criteria: * Receiving a multi-organ transplant or having previous received an organ transplant (including liver re-transplantation) * Receiving an auxiliary graft or in whom a bio-artificial liver (cell system) has been used * Receiving ABO incompatible graft or a graft from a non heart beating donor * Ongoing dosing with systemic corticosteroids * Subjects with systemic infection requiring treatment except viral hepatitis * Diagnosis of new-onset malignancy prior to transplantation, with the exception of basocellular or squamous cell carcinoma of the skin which had been treated successfully. However, subjects with primary liver carcinoma can be included if they meet the following criteria: * \< 3 nodes * no node larger than 5 cm * no metastases * no vascular tumoral invasion * Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer * Subject or donor known to be HIV positive * Known allergy or intolerance to tacrolimus, macrolide antibiotics, corticosteroids, basiliximab or mycophenolate mofetil or any of the product excipients * Pregnant woman or breast-feeding mother * Currently participati…